Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Transl Med ; 15(1): 196, 2017 09 22.
Article in English | MEDLINE | ID: mdl-28938915

ABSTRACT

BACKGROUND: Neurotrophins (NT) belongs to a family of growth factors which promotes neurons survival and differentiation. Increasing evidence show that NT and their receptor are expressed in lung tissues suggesting a possible role in lung health and disease. Here we investigated the expression and functional role of the TrkB/BDNF axis in idiopathic pulmonary fibrotic lung (myo)fibroblasts. METHODS: Lung fibroblast were isolated from IPF patients and characterized for the expression of mesenchymal markers in comparison to normal lung fibroblasts isolated from non-IPF controls. RESULTS: BDNF treatment promoted mesenchymal differentiation and this effect was counteracted by the TrkB inhibitor K252a. In this regard, we showed that K252a treatment was able to control the expression of transcription factors involved in epithelial to mesenchymal transition (EMT). Accordingly, K252a treatment reduced matrix metalloproteinase-9 enzyme activity and E-cadherin expression while increased cytoplasmic ß-catenin expression. CONCLUSIONS: Our results suggest that BDNF/TrkB axis plays a role in EMT promoting the acquisition of (myo)fibroblast cell phenotype in IPF. Targeting BDNF/TrkB seems to represent a viable approach in order to prevent EMT dependent lung fibrosis.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Epithelial-Mesenchymal Transition , Idiopathic Pulmonary Fibrosis/metabolism , Idiopathic Pulmonary Fibrosis/pathology , Receptor, trkB/metabolism , Signal Transduction , Biomarkers/metabolism , Carbazoles/pharmacology , Cell Proliferation/drug effects , Epithelial-Mesenchymal Transition/drug effects , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Indole Alkaloids/pharmacology , Lung/pathology , Male , Middle Aged , Signal Transduction/drug effects
2.
J Transl Med ; 14: 61, 2016 Feb 29.
Article in English | MEDLINE | ID: mdl-26928703

ABSTRACT

BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at a late stage. Moreover patients' responses vary and the outcome is unpredictable. Therefore, the identification of patients who will benefit most of chemotherapy treatment is important for accurate prognostication and better outcome. In this study, using malignant pleural effusions (MPE) from non-small cell lung cancer (NSCLC) patients, we established a collection of patient-derived Adenocarcinoma cultures which were characterized for their sensitivity to chemotherapeutic drugs used in the clinical practice. METHODS: Tumor cells present in MPEs of patients with NSCLC were isolated by density gradient centrifugation, placed in culture and genotyped by next generation sequencing. In a subset of cases patient derived xenografts (PDX) were obtained upon tumor cell inoculation in rag2/IL2 knock-out mice. Isolated primary cultures were characterized and tested for drug sensitivity by in vitro proliferation assays. Additivity, antagonism or synergy for combinatorial treatments were determined by analysis with the Calcusyn software. RESULTS: We have optimized isolation procedures and culture conditions to expand in vitro primary cultures from Malignant Pleural Effusions (MPEs) of patients affected by lung adenocarcinomas, the most frequent form of non small cell lung cancer. Using this approach we have been able to establish 16 primary cultures from MPEs. Cells were banked at low passages and were characterized for their mutational pattern by next generation sequencing for most common driver mutations in lung cancer. Moreover, amplified cultures were shown to engraft with high efficiency when injected in immunocompromised mice. Cancer cell sensitivity to drugs used in standard chemotherapy regimens was assessed either individually or in combination. Differential chemosensitivity and different mutation profiles were observed which suggests that this isolation method could provide a platform for predicting the efficacy of chemotherapy in the clinical setting. Most importantly for six patients it was possible to establish a correlation between drug response in vitro and response to therapy in the clinic. CONCLUSIONS: Results obtained using primary cultured cells from MPEs underscore the heterogeneity of NSCLC in advanced stage as indicated by drug response and mutation profile. Comparison of data obtained from in vitro assays with patients' responses to therapy leads to the conclusion that this strategy may provide a potentially useful approach for evaluating individual chemosensitivity profile and tailor the therapy accordingly. Furthermore, combining MPE-derived primary cultures with their genomic testing allows to identify patients eligible to trials with novel targeted agents.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents/therapeutic use , Lung Neoplasms/drug therapy , Models, Biological , Pleural Effusion, Malignant/drug therapy , Adenocarcinoma/complications , Adenocarcinoma/genetics , Adenocarcinoma of Lung , Aged , Antineoplastic Agents/pharmacology , Biological Assay , Cell Proliferation/drug effects , DNA Mutational Analysis , Erlotinib Hydrochloride/pharmacology , Erlotinib Hydrochloride/therapeutic use , Exome/genetics , Female , Genetic Heterogeneity , Humans , Lung Neoplasms/complications , Lung Neoplasms/genetics , Male , Metabolic Networks and Pathways/drug effects , Mutation/genetics , Pleural Effusion, Malignant/complications , Pleural Effusion, Malignant/genetics , Pleural Effusion, Malignant/pathology , Signal Transduction/drug effects , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
3.
J Cell Physiol ; 231(8): 1745-51, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26633752

ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease, characterized by persistent airflow limitation not fully reversible. However, a number of patients with COPD respond to bronchodilator agents. Some studies have shown polymorphisms in the b2-adrenergic (ADRb2) and muscarinic M2 and M3 receptors (CHRM) that may participate in the modulation of the receptor responses. This study was designed to investigate the existence and the role of adrenergic and muscarinic receptor polymorphisms and their functional impact in COPD. Eighty-two patients with COPD and 17 healthy smokers were recruited and screened for ADRb2 (T164I and R175R), for CHRM2 (rs1824024) and for CHRM3 (-513C/A and -492C/T). Among the polymorphisms studied our results was not able to demonstrate statistically significant association between the polymorphisms studied and COPD risk. Contrarily, we identified, in our COPD population, a significant association with the CHRM2 (rs1824024) polymorphism and disease severity, with lower lung function test values, frequent exacerbations, and poor response to anti-cholinergic drugs. These results suggest the potential role of receptor polymorphism assessment to discriminate newly COPD phenotypes. J. Cell. Physiol. 231: 1745-1751, 2016. © 2015 Wiley Periodicals, Inc.


Subject(s)
Polymorphism, Single Nucleotide , Pulmonary Disease, Chronic Obstructive/genetics , Receptor, Muscarinic M2/genetics , Aged , Aged, 80 and over , Bronchodilator Agents/therapeutic use , Case-Control Studies , Disease Progression , Female , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Lung/physiopathology , Male , Middle Aged , Muscarinic Antagonists/therapeutic use , Phenotype , Polymerase Chain Reaction , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/physiopathology , Receptor, Muscarinic M2/antagonists & inhibitors , Receptor, Muscarinic M3 , Receptors, Adrenergic, beta-2/genetics , Receptors, Muscarinic/genetics , Respiratory Function Tests , Risk Factors , Sequence Analysis, DNA , Severity of Illness Index , Treatment Outcome
4.
J Cell Physiol ; 231(2): 345-56, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26081799

ABSTRACT

The regulatory role of dopamine (DA) in endocrine, cardiovascular and renal functions has been extensively studied and used for clinical purposes. More recently DA has been indicated as a regulatory molecule for immune cells and malignant cell proliferation. We assessed the expression and the functional role DA, DA receptors, and transporters in primary small cell lung cancer (SCLC). By HPLC DA plasma levels were more elevated in SCLC patients in comparison with NSCLC patients and healthy controls. SCLC cell expressed DA D1- and D2-like receptors and membrane and vesicular transporters at protein and mRNA levels. We also investigated the effects of independent D1- or D2-like receptor stimulation on SCLC cell cultures. DA D1 receptor agonist SKF38393 induced the increase of cAMP levels and DARPP-32 protein expression without affecting SCLC growth rate. Cell treatment with the DA D1 receptor antagonist SCH23390 inhibited SKF38393 effects. In contrast, the DA D2 receptor agonist quinpirole (10 µM) counteracted, in a dose and time dependent way, SCLC cell proliferation, it did not affect cAMP levels and decreased phosphorylated AKT that was induced by DA D2 receptor antagonist sulpiride. However, in only one SCLC line, stimulation of DA D2 receptor failed to inhibit cell proliferation in vitro. This effect was associated to the existence of rs6275 and rs6277 polymorphisms in the D2 gene. These results gave more insight into DA control of lung cancer cell behavior and suggested the existence of different SCLC phenotypes.


Subject(s)
Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Receptors, Dopamine/genetics , Receptors, Dopamine/metabolism , Small Cell Lung Carcinoma/genetics , Small Cell Lung Carcinoma/metabolism , Adenylyl Cyclases/metabolism , Aged , Aged, 80 and over , Cell Line, Tumor , Dopamine/blood , Dopamine and cAMP-Regulated Phosphoprotein 32/metabolism , Female , Humans , Male , Middle Aged , Phosphorylation , Polymorphism, Single Nucleotide , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/genetics , RNA, Neoplasm/metabolism , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism
5.
J Neuroimmunol ; 284: 37-43, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-26025056

ABSTRACT

Lymphocytes possess an independent cholinergic system. We assessed the expression of muscarinic cholinergic receptors in lymphocytes from 49 asthmatic children and 10 age matched controls using Western blot. We demonstrated that CD4+ and CD8+ T cells expressed M2 and M4 muscarinic receptors which density were significantly increased in asthmatic children in comparison with controls. M2 and M4 receptor increase was strictly related with IgE and fraction of exhaled nitric oxide (FeNO) measurements and with impairment in objective measurements of airway obstruction. Increased lymphocyte muscarinic cholinergic receptor expression may concur with lung cholinergic dysfunction and with inflammatory molecular framework in asthma.


Subject(s)
Asthma/metabolism , Asthma/pathology , Gene Expression Regulation/physiology , Lymphocytes/metabolism , Receptors, Muscarinic/metabolism , Administration, Inhalation , Adult , Age Factors , Asthma/blood , Asthma/diagnosis , Bronchodilator Agents/administration & dosage , CD4 Antigens/metabolism , CD8 Antigens/metabolism , Case-Control Studies , Child , Female , Gene Expression Regulation/drug effects , Humans , Linear Models , Lymphocytes/drug effects , Male , Nitric Oxide/administration & dosage , Receptors, Muscarinic/genetics , Severity of Illness Index , Statistics, Nonparametric
6.
Cell Cycle ; 12(11): 1696-703, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23656788

ABSTRACT

Lung cancer is the leading cause of cancer-related mortality worldwide. Recent evidence indicates that tumors contain a subpopulation of cancer stem cells (CSCs) that are responsible for tumor maintenance and spread. CSCs have recently been linked to the occurrence of epithelial-to-mesenchymal transition (EMT). Neurotrophins (NTs) are growth factors that regulate the biology of embryonic stem cells and cancer cells, but still little is known about the role NTs in the progression of lung cancer. In this work, we investigated the role of the NTs and their receptors using as a study system primary cell cultures derived from malignant pleural effusions (MPEs) of patients with adenocarcinoma of the lung. We assessed the expression of NTs and their receptors in MPE-derived adherent cultures vs. spheroids enriched in CSC markers. We observed in spheroids a selectively enhanced expression of TrkB, both at the mRNA and protein levels. Both K252a, a known inhibitor of Trk activity, and a siRNA against TrkB strongly affected spheroid morphology, induced anoikis and decreased spheroid forming efficiency. Treatment with neurotrophins reversed the inhibitory effect of K252a. Importantly, TrkB inhibition caused loss of vimentin expression as well as that of a set of transcription factors known to be linked to EMT. These ex vivo results nicely correlated with an inverse relationship between TrkB and E-cadherin expression measured by immunohistochemistry in a panel of lung adenocarcinoma samples. We conclude that TrkB is involved in full acquisition of EMT in lung cancer, and that its inhibition results in a less aggressive phenotype.


Subject(s)
Adenocarcinoma/metabolism , Lung Neoplasms/metabolism , Pleural Effusion, Malignant/metabolism , Receptor, trkB/metabolism , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Anoikis/drug effects , Brain-Derived Neurotrophic Factor/pharmacology , Cadherins/metabolism , Carbazoles/pharmacology , Epithelial-Mesenchymal Transition/drug effects , Humans , Immunohistochemistry , Indole Alkaloids/pharmacology , Lung Neoplasms/pathology , Pleural Effusion, Malignant/pathology , RNA Interference , RNA, Small Interfering/metabolism , Receptor, trkB/antagonists & inhibitors , Receptor, trkB/genetics , Spheroids, Cellular/drug effects , Spheroids, Cellular/metabolism , Transcription Factors/metabolism , Tumor Cells, Cultured , Up-Regulation/drug effects , Vimentin/metabolism
7.
J Cell Physiol ; 228(7): 1516-24, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23444126

ABSTRACT

Autophagy is the main cellular pathway for degradation of long-lived proteins and organelles and regulates cell fate in response to stress. Beclin 1 is a key regulator of this process. In some settings autophagy and apoptosis seem to be interconnected. Recent reports indicate that fibroblasts in idiopathic pulmonary fibrosis (IPF) acquire resistance to apoptosis. Here, we examined the expression of beclin 1, and of the anti apoptotic protein Bcl-2 in human IPF fibroblasts using immunohistochemistry and molecular biology in bioptic sections, in primary cultures of fibroblasts taken from patients with IPF and in fibroblast cell lines. Expression of beclin 1 in fibroblasts from IPF was down-regulated in comparison with fibroblasts from normal lungs while the anti-apoptotic protein Bcl-2 expression was over-expressed. Treatment of fibroblast cell cultures with cisplatin induced a significant increase in beclin 1 and caspase 3 protein levels but a reduction in Bcl-2 expression. These observations were confirmed by the analysis of acid compartments and transmission electron microscopy. Our results demonstrate a modified expression of the apoptotic beclin 1 Bcl-2 proteins in human IPF fibroblasts suggesting the existence of an autophagy/apoptosis system dysfunction.


Subject(s)
Apoptosis Regulatory Proteins/metabolism , Idiopathic Pulmonary Fibrosis/metabolism , Membrane Proteins/metabolism , Apoptosis/drug effects , Apoptosis/physiology , Autophagy/drug effects , Autophagy/physiology , Beclin-1 , Case-Control Studies , Cell Line , Cells, Cultured , Cisplatin/pharmacology , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Idiopathic Pulmonary Fibrosis/pathology , Male , Proto-Oncogene Proteins c-bcl-2/metabolism
8.
J Cell Physiol ; 228(1): 235-41, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22689412

ABSTRACT

Homeodomain-interacting protein kinase 2 (Hipk2) is an emerging player in cell response to genotoxic agents that contributes to the cell's decision between cell cycle arrest or apoptosis. HIPK2 acts as co-regulator of an increasing number of transcription factors and modulates many different basic cellular processes such as apoptosis, proliferation, DNA damage response, differentiation. Idiopathic pulmonary fibrosis (IPF) is characterized by an anatomical disarrangement of the lung due to fibroblast proliferation, extracellular matrix deposition and lung function impairment. Although the role of inflammation is still debated, attention has been focused on lung cell functions as fibroblast phenotype and activity. Aim of the present study was to analyze the loss of heterozygosity (LOH) at HIPK2 locus 7q32.34 in human lung fibroblasts and the HIPK2 expression in 15 IPF samples and in four primary fibroblast cell cultures isolated from IPF biopsies using semi-quantitative RT-PCR, Western blots and immunohistochemistry. We demonstrated a frequency of LOH in IPF fibroblasts of 46% for the internal D7S6440 microsatellite and 26.6% for the external D7S2468 microsatellite. Furthermore, we demonstrated low HIPK2 protein expression in those fibroblasts from IPF patients that present the HIPK2 LOH. The restoration of HIPK2 expression in IPF derived cells induced a significant reduction of chemoresistance after treatment with cisplatin. The results obtained allow us to hypothesize that HIPK2 dysfunction may play a role in fibroblasts behavior and in IPF pathogenesis. HIPK2 may be considered as a novel potential target for anti-fibrosis therapy.


Subject(s)
Carrier Proteins/metabolism , Idiopathic Pulmonary Fibrosis/metabolism , Protein Serine-Threonine Kinases/metabolism , Aged , Antineoplastic Agents/pharmacology , Carrier Proteins/genetics , Cell Line , Cisplatin/pharmacology , Drug Resistance, Neoplasm , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression Regulation/physiology , Humans , Idiopathic Pulmonary Fibrosis/pathology , Loss of Heterozygosity , Lung/cytology , Male , Middle Aged , Protein Serine-Threonine Kinases/genetics
9.
Growth Factors ; 28(4): 221-31, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20214505

ABSTRACT

Neurotrophins (NTs) expression was assessed in malignant and non-malignant pleural effusions (inflammatory exudates and transudates). Enzyme-linked immunosorbent assay, in malignant exudates from small and non-small cell lung cancer (SCLC and NSCLC), detected nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), and their levels are higher as compared with inflammatory and transudative effusions. By immunoblots, in cultured cancer cells coming from malignant pleural effusions, NTs and low- and high-affinity NT receptors were detected in a percentage of SCLC and NSCLC. Proliferation assay demonstrated that BDNF significantly increased cancer cell proliferation in vitro, on the contrary, NT-3 reduced cancer cell growth rate and NGF did not modify cell growth. Moreover, NGF protects cells from death during starvation. These effects are reverted by the addition of NT receptor antagonists. Cultured cancer cells injected into the lung of immunodeficient mice generate lung tumors expressing NTs and NT receptors. These findings suggest that NTs may be able to modulate cancer cell behavior and their growth.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Nerve Growth Factors/metabolism , Neurotrophin 3/metabolism , Pleural Effusion, Malignant/metabolism , Pleural Effusion/metabolism , Receptors, Nerve Growth Factor/metabolism , Aged , Aged, 80 and over , Animals , Blotting, Western , Brain-Derived Neurotrophic Factor/blood , Brain-Derived Neurotrophic Factor/pharmacology , Carcinoma, Non-Small-Cell Lung/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Gene Expression , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Lung/pathology , Lung Neoplasms/metabolism , Male , Mice , Mice, Inbred NOD , Mice, SCID , Middle Aged , Neoplasm Transplantation , Nerve Growth Factors/blood , Nerve Growth Factors/pharmacology , Neurotrophin 3/blood , Neurotrophin 3/pharmacology , Pleural Effusion/genetics , Pleural Effusion, Malignant/genetics , Receptor, trkB/metabolism , Signal Transduction , Small Cell Lung Carcinoma/metabolism , Tumor Cells, Cultured
10.
Sarcoidosis Vasc Diffuse Lung Dis ; 24(1): 13-23, 2007 Mar.
Article in English | MEDLINE | ID: mdl-18069415

ABSTRACT

BACKGROUND AND AIM OF THE STUDY: Idiopathic interstitial pneumoniae (IIPs) are characterized by fibroblast proliferation, extracellular matrix deposition and progressive lung function impairment. Because effective therapeutic strategies still remain limited, research has been directed toward the identification of novel targets for additional therapeutic options. The neurotrophins (NTs) nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and NT-3, beside their importance in nervous, endocrine and immune system activities, participate in chronic inflammatory disorders and in repair processes. METHODS: We have investigated NT and high and low affinity NT receptor expression in IIPs using immunoblots and immunohistochemistry. Fourteen idiopatic pulmonary fibrosis/usual interstitial pneumoniae (IPF/UIP), eight non specific pneumoniae (NSIP) and eight respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) were analyzed. RESULTS: Immunoblots revealed that NT and high affinity NT receptor proteins were more abundantly expressed in IPF/UIP than NSIP and RB-ILD patients. In RB-ILD, a faint expression of NT-3 and NT receptors were detected. NT and NT receptor immunostaining was detected in interstitial cells from IPF/UIP, NSIP and RB-ILD patients by immunohistochemistry. Fibroblastic foci in IPF/UIP strongly stained for BDNF and its high affinity receptor TrkB and in lesser amount for NGF, NT-3 and their respective high affinity receptors TrkA and TrkC. Furthermore, in fibroblast culture derived from IPF/UIP patients, the proliferation rate of primary culture and clones derived from primary lines was stimulated by BDNF but down regulated by NT-3. In contrast, NGF did not influence IPF/UIP fibroblasts proliferation. CONCLUSIONS: Our data suggest that that NTs may exert differential activities on lung fibroblasts and may be considered as potential regulatory molecules influencing fibroblast behavior in IPF/UIP patients. Therefore, NTs may play a role in IIPs patho-physiology representing novel potential therapeutic targets.


Subject(s)
Lung Diseases, Interstitial/metabolism , Lung/metabolism , Nerve Growth Factors/metabolism , Pulmonary Fibrosis/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Adult , Aged , Brain-Derived Neurotrophic Factor/analysis , Brain-Derived Neurotrophic Factor/metabolism , Female , Fibroblasts/cytology , Fibroblasts/metabolism , Humans , Immunohistochemistry , Male , Middle Aged , Nerve Growth Factor/analysis , Nerve Growth Factor/metabolism , Nerve Growth Factors/analysis , Neurotrophin 3/analysis , Neurotrophin 3/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...